

CRO Communiqué

Keeping you informed about CRO progress

January 2015

Top Enrolling Physicians for December 2014

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Bechtel (Mercy St. Louis)	1	1	0	1
Dr. Cunningham (Cox)	1	0	1	1
Dr. Donegan (Mercy St. Louis)	1	0	1	1
Dr. Holden (Mercy Spfld)	1	0.24	0	0.24
Dr. Miller (Freeman)	1	1	0	1
Dr. Oza (Mt. Vernon)	2	0.5	1	1.5
Dr. Toothaker (Phelps)	1	1	0	1
Dr. Tiriveedhi (Mercy Spfld)	1	1	0	1
TOTALS	9	4.74	3	7.74

Our enrollments have been exceptionally low for December. Hopefully, with the New Year our enrollments will see a steady increase.

Unfortunately, we have been notified that we have been counting our earned credits incorrectly since the beginning of the NCORP program in August. NCI's NCORP System, management program has not been updated with credits earned for enrollments. We had been gathering this information from the CTSU website and counting our credits based on what was posted there. We have now been informed that credits posted on the CTSU site is for funding only. Therefore, CRO has fewer credits than previously reported. When the NCORP System is updated we will recalculate our credits. This month's credits as noted above are correct to the best of our knowledge.

Study Profile

A221301 - Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy is our profile study this month. This randomized placebo controlled trial studies antiemetic therapy with olanzapine to see how well they work compared to antiemetic therapy alone in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic (causes vomiting) chemotherapy. Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. Olanzapine may help prevent chemotherapy-induced nausea and vomiting by blocking brain receptors that appear to be involved in nausea and vomiting.

NRG Audit

CRO has been notified we will be audited on February 17, 18 and 19th by the NRG research base. All NCI research bases are required to audit NCORP programs at least every 3 years. All component sites are required to bring selected charts to be audited to the Administrative office in Springfield, MO.

Cancer Care Delivery Research (CCDR)

We have several applicants for our Cancer Care Delivery Research coordinator position. We will begin interviews next week.

**Hope you all have a blessed
2015. May it be filled with
many CRO enrollments
to NCI clinical trials!!**



New Studies Approved in December, 2014 Through Mercy's IRB

NRG-CC002 - Pre-Operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers

**Approved for use at Mercy Springfield, Mercy St. Louis, and Cox*

New Studies Approved and Opened in December with the CIRB

None

Closed Studies in December, 2014

SWOG S1400E - Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

**Only sub-study E is closed*

Temporarily Closed in December, 2014

Alliance A030201 – 12/11/2014 Enzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

AOST1322 – 12/15/2014 Phase II Study of Eribulin (NSC#707389, IND#122686) in Recurrent or Refractory Osteosarcoma

GOG-0283 – 12/19/2014 A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, Endometrial, or Endometriosis-Associated Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression